Putative neuroprotective pharmacotherapies to target the staged progression of mental illness
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Aim: Neuropsychiatric disorders including depression, bipolar and schizophrenia frequently exhibit a neuroprogressive course from prodrome to chronicity. There are a range of agents exhibiting capacity to attenuate biological mechanisms associated with neuroprogression. This review will update the evidence for putative neuroprotective agents including clinical efficacy, mechanisms of action and limitations in current assessment tools, and identify novel agents with neuroprotective potential. Method: Data for this review were sourced from online databases PUBMED, Embase and Web of Science. Only data published since 2012 were included in this review, no data were excluded based on language or publication origin. Results: Each of the agents reviewed inhibit one or multiple pathways of neuroprogression including: inflammatory gene expression and cytokine release, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophin dysregulation and apoptotic signalling. Some demonstrate clinical efficacy in preventing neural damage or loss, relapse or cognitive/functional decline. Agents include: the psychotropic medications lithium, second generation antipsychotics and antidepressants; other pharmacological agents such as minocycline, aspirin, cyclooxygenase‐2 inhibitors, statins, ketamine and alpha‐2‐delta ligands; and others such as erythropoietin, oestrogen, leptin, N‐acetylcysteine, curcumin, melatonin and ebselen. Conclusions: Signals of evidence of clinical neuroprotection are evident for a number of candidate agents. Adjunctive use of multiple agents may present a viable avenue to clinical realization of neuroprotection. Definitive prospective studies of neuroprotection with multimodal assessment tools are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects
Haijma, S. V., Van Haren, N., Cahn, W., Koolschijn, P. C. M. P., Hulshoff Pol, H. E., & Kahn, R. S. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs118 · Cited by 1,012
Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
Molendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702 · cited 2×
“A recent systematic review and meta-analysis of depressed patients (n = 2384 antidepressant-free patients and n = 1249 antidepressant-treated patients) vs healthy controls (n = 2982) suggests antidepressant treatment rectifies deficits in peripheral BDNF (Molendijk et al., 2014); possibly as a secondary result of cent…”
BackgroundGlutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Kreisel, T., Frank, M. G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M. V., Maier, S. F., & Yirmiya, R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.155 · Cited by 663
Wise, T., Radua, J., Via, E., Cardoner, N., Abe, O., Adams, T. M., Amico, F., Cheng, Y., Cole, J. H., de Azevedo Marques Périco, C., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.72 · Cited by 606
Fusar-Poli, P., Smieskova, R., Kempton, M. J., Ho, B. C., Andreasen, N. C., & Borgwardt, S. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.06.001 · Cited by 512
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Self-citationHannon, E., Dempster, E., Viana, J., Burrage, J., Smith, A. R., Macdonald, R., St Clair, D., Mustard, C., Breen, G., Therman, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1041-x · Cited by 349 · cited 1×
“This hypothesis was supported in a multicentre epigenome wide analysis of schizophrenic patients vs controls (n = 1714) (Hannon et al., 2016).”
ResultHolmes, S. E., Hinz, R., Conen, S., Gregory, C. J., Matthews, J. C., Anton-Rodriguez, J. M., Gerhard, A., & Talbot, P. S. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.005 · Cited by 346
McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., Berger, G. E., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2902 · Cited by 262
Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233
Mattei, D., Ivanov, A., Ferrai, C., Jordan, P., Guneykaya, D., Buonfiglioli, A., Schaafsma, W., Przanowski, P., Deuther-Conrad, W., Brust, P., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.80 · Cited by 222 · cited 1×
“In a follow-up study, Mattei et al. (2017) applied RNA- sequencing to hippocampal microglia isolated from these mice.”
BackgroundCurcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study
Lopresti, A. L., Maes, M., Maker, G. L., Hood, S. D., & Drummond, P. D. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.001 · Cited by 216 · cited 1×
“This pathway, an indicator of anabolic states, is up-regulated in hippocampal neurones following an antidepressant dose of atorvastatin in mice (Ludka et al., 2016).”
BackgroundMiyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212
Garza, J. C., Guo, M., Zhang, W., & Lu, X.-Y. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.161 · Cited by 209
Alboni, S., van Dijk, R. M., Poggini, S., Milior, G., Perrotta, M., Drenth, T., Brunello, N., Wolfer, D. P., Limatola, C., Amrein, I., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2015.142 · Cited by 207
Juvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia
Cabungcal, J.-H., Counotte, D. S., Lewis, E. M., Tejeda, H. A., Piantadosi, P., Pollock, C., Calhoon, G. G., Sullivan, E. M., Presgraves, E., Kil, J., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.028 · Cited by 204
Chiappini, S., & Schifano, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0359-y · Cited by 189 · cited 1×
“The alpha 2 delta (α2δ) ligands pregabalin and gabapentin are used as treatments for neuropathic pain and have recently become known for their abuse potential (Chiappini & Schifano, 2016; Peckham, Fair- man, & Sclar, 2017).”
BackgroundCheng, Y., Pardo, M., Armini, R. D. S., Martinez, A., Mouhsine, H., Zagury, J.-F., Jope, R. S., & Beurel, E. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.12.012 · Cited by 174
Oxidative stress in early stage Bipolar Disorder and the association with response to lithium
de Sousa, R. T., Zarate, C. A., Zanetti, M. V., Costa, A. C., Talib, L. L., Gattaz, W. F., & Machado-Vieira, R. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.11.011 · Cited by 169 · cited 1×
“Mechanistically, lithium may reduce the oxidative stress burden seen in bipolar disorder (de Sousa et al., 2014; De Sousa, Zanetti, Talib, Gattaz, & Machado-Vieira, 2013).”
BackgroundMunkholm, K., Vinberg, M., & Kessing, L. V. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.54 · Cited by 157
Liu, D., Wang, Z., Gao, Z., Xie, K., Zhang, Q., Jiang, H., & Pang, Q. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.068 · Cited by 151
Gałecki, P., Gałecka, E., Maes, M., Chamielec, M., Orzechowska, A., Bobińska, K., Lewiński, A., & Szemraj, J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.016 · Cited by 141
das Neves Duarte, J. M., Kulak, A., Gholam-Razaee, M. M., Cuenod, M., Gruetter, R., & Do, K. Q. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.07.035 · Cited by 124 · cited 1×
“NAC is a glutathione precursor and potent antioxidant; as demon- strated by reversal of a glutathione-deficient mouse model of schizo- phrenia (das Neves Duarte et al., 2012).”
BackgroundSalagre, E., Fernandes, B. S., Dodd, S., Brownstein, D. J., & Berk, M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.047 · Cited by 117
Self-citationMorgan, C. J. A., Dodds, C. M., Furby, H., Pepper, F., Fam, J., Freeman, T. P., Hughes, E., Doeller, C., King, J., Howes, O., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00149 · Cited by 110 · cited 2×
“Furthermore, chronic ketamine abuse is associated with an irreversible decline in brain func- tion (Morgan et al., 2014).”
BackgroundA randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia
Bentsen, H., Osnes, K., Refsum, H., Solberg, D. K., & Bøhmer, T. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.110 · Cited by 97
Abbasi, S. H., Mohammadinejad, P., Shahmansouri, N., Salehiomran, A., Beglar, A. A., Zeinoddini, A., Forghani, S., & Akhondzadeh, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.049 · Cited by 70
Vincenzi, B., Stock, S., Borba, C. P. C., Cleary, S. M., Oppenheim, C. E., Petruzzi, L. J., Fan, X., Copeland, P. M., Freudenreich, O., Cather, C., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.021 · Cited by 67 · cited 1×
“Neither pravastatin nor lovastatin add-on therapies were shown to lessen symptom severity in schizophrenia, though pravastatin-reduced peripheral inflammatory markers (Ghanizadeh, Rezaee, Dehbozorgi, Berk, & Akhondzadeh, 2014; Vincenzi et al., 2014).”
BackgroundMorais, M., Patrício, P., Mateus-Pinheiro, A., Alves, N. D., Machado-Santos, A. R., Correia, J. S., Pereira, J., Pinto, L., Sousa, N., & Bessa, J. M. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.120 · Cited by 56
Simvastatin treatment exerts antidepressant-like effect in rats exposed to chronic mild stress
Lin, P.-Y., Chang, A. Y. W., & Lin, T.-K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.06.006 · Cited by 43
Chaves, C., Marque, C. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., Ferrari, T. B., Santos, A. C., Araújo, D., Machado-de-Sousa, J. P., Bressan, R. A., Elkis, H., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.031 · Cited by 41
Smesny, S., Milleit, B., Schaefer, M. R., Hipler, U.-C., Milleit, C., Wiegand, C., Hesse, J., Klier, C. M., Holub, M., Holzer, I., et al. (2015) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.07.001 · Cited by 36 · cited 1×
“In young psychotic patients, or those at ultra-high risk of psychosis, omega-3 PUFA supplementation increased total antioxidant capacity and reduced symptom severity (Pawelczyk, Grancow-Grabka, Trafalska, Szemraj, & Pawelczyk, 2017; Smesny et al., 2015).”
BackgroundSelf-citationKrivoy, A., Hochman, E., Sendt, K.-V., Hollander, S., Vilner, Y., Selakovic, M., Weizman, A., & Taler, M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.05.040 · Cited by 33 · cited 2×
“This is a poignant finding as serum levels of BDNF are decreased in antipsychotic naïve schizophrenic patients and increased in clozapine responders (Krivoy et al., 2018; Toll & Mane, 2015).”
BackgroundDaglas, R., Cotton, S. M., Allott, K., Yücel, M., Macneil, C. A., Hasty, M. K., Murphy, B., Pantelis, C., Hallam, K. T., Henry, L. P., et al. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2015.09.460 · Cited by 31 · cited 1×
“Meta-analysis suggests add-on statin therapy improves depressive symptoms with good tolerability (Salagre, Fernandes, Dodd, Brownstein, & Berk, 2016); however, larger prospective trials are required to confirm this.”
BackgroundSelf-citationKudlek Mikulic, S., Mihaljevic-Peles, A., Sagud, M., Bajs Janovic, M., Ganoci, L., Grubisin, J., Kuzman Rojnic, M., Vuksan Cusa, B., Bradaš, Z., & Božina, N. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1340518 · Cited by 25 · cited 1×
“Olanzapine Olanzapine did not increase plasma BDNF in a 6-week prospective study of schizophrenic patients (n = 50) (Kudlek Mikulic et al., 2017).”
Background
Cited by
Hickie, I. B., Scott, E. M., Cross, S. P., Iorfino, F., Davenport, T. A., Guastella, A. J., Naismith, S. L., Carpenter, J. S., Rohleder, C., Crouse, J. J., et al. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50383 · Cited by 208
The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., Pacchiarotti, I., Vieta, E., & Berk, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.546801 · Cited by 140
“It can prevent oxidative damage to complex I (184), can enhance GST activity, and act directly against oxidant radicals (290, 291).”
BackgroundInfluentialNeurodevelopmental pathways in bipolar disorder
Kloiber, S., Rosenblat, J. D., Husain, M. I., Ortiz, A., Berk, M., Quevedo, J., Vieta, E., Maes, M., Birmaher, B., Soares, J. C., et al. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.005 · Cited by 122
Self-citationIn vitro effects of antipsychotics on mitochondrial respiration
Cikánková, T., Fišar, Z., Bakhouche, Y., Ľupták, M., & Hroudová, J. (2019) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-019-01665-8 · Cited by 44
Clinical Staging for Youth Mental Disorders: Progress in Reforming Diagnosis and Clinical Care
McGorry, P. D., & Mei, C. (2021) · Annual Review of Developmental Psychology · doi:10.1146/annurev-devpsych-050620-030405 · Cited by 38
Metadata
- Authors
- Robertson, O. D., Coronado, N. G., Sethi, R., Berk, M., & Dodd, S.
- Venue
- Early Intervention in Psychiatry
- Publisher
- Wiley
- Published
- 2019-01-28
- Volume
- 13
- Issue
- 5
- Pages
- 1032-1049
- ISSN
- 1751-7885 (ISSN-L)
- 1751-7893
- OpenAlex
- W2911377666
- Cited by
- 52
- References
- 38
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.